Mimark

The AI engine Fit Assessment

Beta

The company will be attending the 2024 Health Tech Forward Event

Blurb

MiMARK focuses on improving the accuracy and efficiency of diagnostics for endometrial cancer.

HQ Location

Spain

Founded

2021

Employees

1 - 10

Total funding raised

$7.10M

Last Funding Event

Seed, $4.22M, November 28, 2023

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M

Developer of a women's health platform designed to reshape gynecological diagnostics. The company offers services that envision the gynecological fluid as the next step in liquid biopsy in gynecology, a comprehensive diagnostics portfolio to drive innovation and positive change in women's healthcare, WomEC, an IVD (in vitro diagnostics) for EC and additional products related to EC diagnosis (endometrial cancer screening test for high-risk population, but also to tackle other gynecological diseases affecting the lower gynecological tract, such as endometriosis and ovarian cancer, enabling users with the development and validation stages of innovative systems for women's health following quality and regulatory requirements, including prototype development, clinical validation and utility, and IP (Intraperitoneal injection) improvement.